These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21945487)

  • 21. Inflation of the type I error: investigations on regulatory recommendations for bioequivalence of highly variable drugs.
    Wonnemann M; Frömke C; Koch A
    Pharm Res; 2015 Jan; 32(1):135-43. PubMed ID: 25033764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.
    Labes D; Schütz H
    Pharm Res; 2016 Nov; 33(11):2805-14. PubMed ID: 27480875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
    Nguyen TT; Bazzoli C; Mentré F
    Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the statistical model of the two-stage designs in bioequivalence assessment.
    Karalis V; Macheras P
    J Pharm Pharmacol; 2014 Jan; 66(1):48-52. PubMed ID: 24175961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence studies: a new EMA guideline.
    Houin G
    Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464
    [No Abstract]   [Full Text] [Related]  

  • 31. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioequivalence: switchability and scaling.
    Midha KK; Rawson MJ; Hubbard JW
    Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects.
    Mathew P; Mandal J; Patel K; Soni K; Tangudu G; Patel R; Kale P
    Clin Ther; 2011 Sep; 33(9):1105-19. PubMed ID: 21840601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
    Montague TH; Potvin D; Diliberti CE; Hauck WW; Parr AF; Schuirmann DJ
    Pharm Stat; 2012; 11(1):8-13. PubMed ID: 21308974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limits for the scaled average bioequivalence of highly variable drugs and drug products.
    Tothfalusi L; Endrenyi L
    Pharm Res; 2003 Mar; 20(3):382-9. PubMed ID: 12669957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.